Fang Fang Zhang1,2, Shanshan Liu1, Mei Chung3, Michael J Kelly4,5. 1. Department of Nutrition Sciences, Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts. 2. Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts. 3. Department of Public Health and Community Medicine, Nutrition/Infection Unit, Tufts University School of Medicine, Boston, Massachusetts. 4. Division of Pediatric Hematology/ Oncology, The Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts. 5. Department of Pediatrics, Tufts University School of Medicine, Boston, Massachusetts.
Abstract
BACKGROUND: Survivors of pediatric acute lymphoblastic leukemia (ALL) have a significantly higher body mass index (BMI) than their peers. Understanding the critical time periods in which patients with pediatric ALL are vulnerable to unhealthy weight gain will lay the groundwork for developing effectively timed interventions. PROCEDURE: We determined the growth patterns of patients with pediatric ALL during and after treatment through the conduct of a systematic review and meta-analysis. A search of MEDLINE, Scopus, and Web of Science was performed from its inception through May 2014. Studies met the inclusion criteria if they included at least 10 patients of pediatric ALL, and longitudinally assessed BMI at diagnosis and at least one time point after diagnosis RESULTS: Twenty-one studies met the inclusion criteria for the systematic review and 16 were included in meta-analysis. The mean increase in BMI z-score during treatment in 1,514 patients with pediatric ALL was 0.81 (95% CI: 0.25-1.38). Specifically, patients experienced substantial weight gain in early treatment (Δ = 0.41, 95% CI: -0.34, 1.17) and again during maintenance (Δ = 0.34, 95% CI:-0.22, 0.90). The mean increase in BMI z-score ranged between 0.52 and 0.89 beyond treatment completion. Subgroup analyses found unhealthy weight gain occurred regardless of patients' receipt of cranial radiation therapy, sex, and, weight status at diagnosis. CONCLUSIONS: Patients with pediatric ALL experience unhealthy weight gain early in treatment, and increases in weight are maintained beyond treatment completion. Preventing early onset of obesity is a priority for improving the care and outcomes for patients with pediatric ALL.
BACKGROUND: Survivors of pediatric acute lymphoblastic leukemia (ALL) have a significantly higher body mass index (BMI) than their peers. Understanding the critical time periods in which patients with pediatric ALL are vulnerable to unhealthy weight gain will lay the groundwork for developing effectively timed interventions. PROCEDURE: We determined the growth patterns of patients with pediatric ALL during and after treatment through the conduct of a systematic review and meta-analysis. A search of MEDLINE, Scopus, and Web of Science was performed from its inception through May 2014. Studies met the inclusion criteria if they included at least 10 patients of pediatric ALL, and longitudinally assessed BMI at diagnosis and at least one time point after diagnosis RESULTS: Twenty-one studies met the inclusion criteria for the systematic review and 16 were included in meta-analysis. The mean increase in BMI z-score during treatment in 1,514 patients with pediatric ALL was 0.81 (95% CI: 0.25-1.38). Specifically, patients experienced substantial weight gain in early treatment (Δ = 0.41, 95% CI: -0.34, 1.17) and again during maintenance (Δ = 0.34, 95% CI:-0.22, 0.90). The mean increase in BMI z-score ranged between 0.52 and 0.89 beyond treatment completion. Subgroup analyses found unhealthy weight gain occurred regardless of patients' receipt of cranial radiation therapy, sex, and, weight status at diagnosis. CONCLUSIONS:Patients with pediatric ALL experience unhealthy weight gain early in treatment, and increases in weight are maintained beyond treatment completion. Preventing early onset of obesity is a priority for improving the care and outcomes for patients with pediatric ALL.
Authors: Whitney D Arroyave; Elizabeth C Clipp; Paige E Miller; Lee W Jones; Dianne S Ward; Melanie J Bonner; Philip M Rosoff; Denise Clutter Snyder; Wendy Demark-Wahnefried Journal: Oncol Nurs Forum Date: 2008-01 Impact factor: 2.172
Authors: Robert L C Harper; Richard A L Breene; Michael Gattens; Rachel M Williams; Matthew J Murray Journal: Br J Haematol Date: 2013-09-14 Impact factor: 6.998
Authors: Melissa M Hudson; Kirsten K Ness; James G Gurney; Daniel A Mulrooney; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Gregory T Armstrong; Kerri A Nottage; Kendra E Jones; Charles A Sklar; Deo Kumar Srivastava; Leslie L Robison Journal: JAMA Date: 2013-06-12 Impact factor: 56.272
Authors: Kyong-Won Bang; Soo Young Seo; Jae Wook Lee; Pil-Sang Jang; Min Ho Jung; Nack-Gyun Chung; Bin Cho; Dae-Chul Jeong; Byung Kyu Suh; Hack-Ki Kim Journal: Korean J Pediatr Date: 2012-04-30
Authors: Austin L Brown; Philip J Lupo; Heather E Danysh; Mehmet F Okcu; Michael E Scheurer; Kala Y Kamdar Journal: J Pediatr Hematol Oncol Date: 2016-08 Impact factor: 1.289
Authors: Emily K Browne; Yinmei Zhou; Wassim Chemaitilly; John C Panetta; Kirsten K Ness; Sue C Kaste; Cheng Cheng; Mary V Relling; Ching-Hon Pui; Hiroto Inaba Journal: Cancer Date: 2018-10-25 Impact factor: 6.860
Authors: Brianna R Murphy; Margaret P Raber; Karla D Crawford; Leslie Grasse; Lisa Wartenberg; Jimin Wu; Seyedeh S Dibaj; Joya Chandra Journal: Child Obes Date: 2020-03-13 Impact factor: 2.992